Pfizer Inc's Revenue in the fiscal year 2025 $ 62,579.00 millions
Pfizer Inc's Revenue in the fiscal year 2024 $ 63,627.00 millions
Pfizer Inc's Revenue in the fiscal year 2023 $ 58,496.00 millions
Pfizer Inc's Revenue in the fiscal year 2022 $ 100,330.00 millions
Pfizer Inc's Revenue in the fiscal year 2021 $ 81,288.00 millions
PFE Revenue second quarter 2026 Y/Y Growth Comment
Pfizer Inc reported Revenue growth of 2.6% year on year in the second quarter 2026, to $ 15,034.00 millions, this is lower than Pfizer Inc's recent average Revenue growth of 5.27%.
Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 125 other companies have achieved higher Revenue growth. While Pfizer Inc' s Revenue increase of 2.6% ranks overall at the positon no. 2526 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Pfizer Inc's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
145.2 %
1.52 %
-50.98 %
(Apr 04 2021)
PFE's II. Quarter Q/Q Revenue Comment
Pfizer Inc achieved in the II. Quarter 2026 above company average sequential Revenue growth of 4.03%, to $ 15,034.00 millions, from $14,451.00 millions in the first quarter.
Within Major Pharmaceutical Preparations industry 71 other companies have achieved higher Revenue quarter on quarter growth. While Pfizer Inc's Revenue growth quarter on quarter, overall rank is 1243.
Pfizer Inc achieved in the II. Quarter 2026 above company average sequential Revenue growth of 4.03%, to $ 15,034.00 millions, from $14,451.00 millions in the first quarter.
Within Major Pharmaceutical Preparations industry 71 other companies have achieved higher Revenue quarter on quarter growth. While Pfizer Inc's Revenue growth quarter on quarter, overall rank is 1243.
Pfizer Inc's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 28 2026)
12 Months Ending (Mar 29 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 28 2025)
12 Months Ending (Jun 29 2025)
Cumulative Revenue 12 Months Ending
$ 63,696.00
$ 63,315.00
$ 62,579.00
$ 62,785.00
$ 63,833.00
Y / Y Revenue Growth (TTM)
-0.21 %
1.36 %
-1.65 %
4.45 %
14.19 %
Year on Year Revenue Growth Overall
Ranking
# 1128
# 1050
# 1316
# 2889
# 1239
Seqeuential Revenue Change (TTM)
0.6 %
1.18 %
-0.33 %
-1.64 %
2.19 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2402
# 2395
# 1611
# 1330
# 846
Cumulative Revenue growth Comment
For the 12 months ended Jun 28 2026 Pfizer Inc reported a decrease in Revenue by -0.21% year on year, to $63,696 millions, compare to the 1.36% growth at Mar 29 2026.
In the Healthcare sector 213 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1050 to 1128.
For the 12 months ended Jun 28 2026 Pfizer Inc reported a decrease in Revenue by -0.21% year on year, to $63,696 millions, compare to the 1.36% growth at Mar 29 2026.
In the Healthcare sector 213 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1050 to 1128.
About Pfizer Inc Revenue Growth Rates (PFE), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
4.48%